Angiokardil - instructions for use, dose, side effects, contraindications

Inhibits gamma-butyrobetaine hydroxylase, reduces the synthesis of carnitine and transport of long chain fatty acids through the cell membranes, prevents the accumulation of activated forms of unoxidized fatty acids - acylcarnitine and acylcoenzyme A derivatives - in cells. As a result of decreasing carnitine concentration, gamma-butyrobetaine is strongly synthesized and has vasodilating properties. In the case of acute ischemic damage, the myocardium slows the formation of the necrotic zone, shortens the rehabilitation period. In chronic heart failure (CHF) increases tolerance to physical activity. When angina pectoris reduces the frequency of attacks.In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the source of ischemia, promotes redistribution of blood in favor of ischemic site. Effective in the case of vascular and dystrophic pathology of the fundus.

Stimulates physical working capacity, reduces the severity of symptoms of mental and physical overstrain. Activates cellular and humoral immunity. Eliminates vegetative manifestations in chronic alcoholism and abstinence.

Pharmacokinetics:

Bioavailability with intravenous injection - 100%. The maximum concentration (C_m_Oh) in the blood plasma is achieved immediately after its administration.

Metabolism: metabolized in the body with the formation of two major metabolites, which are excreted by the kidneys.

Excretion: half-life (T_1/2) is 3-6 hours.

Indications:

- In complex therapy ischemic heart disease (angina pectoris, myocardial infarction), chronic cardiac insufficiency, cardialgia against the background of dyshormonal cardiomyopathy.

- In the complex therapy of cerebral circulation disorders (ischemic stroke, cerebrovascular insufficiency).

- Reduced performance, mental and physical overload (including athletes).

- Alcohol abstinence syndrome (in combination with specific therapy of alcoholism).

- In the complex therapy of hemophthalmia and hemorrhage into the retina of various etiologies, thrombosis of the central vein of the retina and ce branches, retinopathies of various etiologies (diabetic, hypertonic).

Contraindications:

Increased individual sensitivity to the drug, increased intracranial pressure (with violation of venous outflow and intracranial tumors), pregnancy, the period of breastfeeding, age to 18 years (efficacy and safety not established).

Carefully:

In diseases of the liver and / or kidney.

Pregnancy and lactation:

Contraindicated in pregnancy. For the duration of treatment, breastfeeding should be discontinued.

Dosing and Administration:

Intravenous (intravenously), intramuscularly (in / m), parabulbar. In view of the possible development of an exciting effect, it is recommended to apply in the morning. The mode of administration, dose and duration of the course of treatment are set individually, depending on the indications, the severity of the condition,

Angina pectoris and myocardial infarction (as part of complex therapy):

Myocardial infarction. Intravenously spray 500-1000 mg (5-10 ml solution for injection 100 mg / ml) 1 once a day or by dividing the dose into 2 introduction, then switch to taking the drug inside.

Stable angina. Intravenously struino 500-1000 mg (5-10 ml solution for injection 100 mg / ml) I once a day or divided the dose into 2 injections, or intramuscularly 500 mg 1-2 times a day, the course of treatment 10-14 days, then switch to taking the drug inside. The general course of treatment is 4-6 weeks.

Chronic cardiac Insufficiency and cardialgia on the background of dyshormonal cardiomyopathy (as part of complex therapy):

Intravenously spray 500-1000 mg (5-10 ml solution for injection 100 mg / ml) once a day or divided the dose into 2 injections, or intramuscularly 500 mg 1-2 times a day, the course of treatment 10-14 days, then switch to taking the drug inside. The general course of treatment is 4-6 weeks.

Violation cerebral blood circulation (as part of complex therapy):

In the acute phase of 500 mg (5 ml solution for injection 100 mg / ml) 1 time per day intravenously for 10 days, then switch to taking the drug inside. The general course of treatment is 4-6 weeks. With chronic insufficiency of the brain blood circulation 500 mg (5 ml solution for injection 100 mg / ml) I once a day, intravenously or intramuscularly for 10 days, then switch to taking the drug inside. The general course of treatment is 4-6 weeks. Repeated courses (usually 2-3 times a year) are possible after consultation with a doctor.

Physical and mental overloads:

Intramuscularly or intravenously, 500 mg (5 ml solution for injection) once a day; course of treatment 10-14 days. If necessary, repeat the course after 2-3 weeks.

Alcohol abstinence syndrome (as part of complex therapy):

Intravenous or intramuscular injection of 500 mg (5 ml solution for injection) 2 times a day; course of treatment 7-10 days.

Hemophthalmia and hemorrhage into the retina of various etiologies, thrombosis of the central vein of the retina and its branches, retinopathy (as part of complex therapy):

Parabulbarno injected into 50 mg (0.5 ml) of the drug solution for 10 days.

Side effects:

From the side of the cardiovascular system: rarely - tachycardia, a decrease or increase in blood pressure.

From the central nervous system: rarely - psychomotor agitation, insomnia.

From the digestive system: rarely - dyspeptic disorders Allergic reactions: rarely - skin itching, rash, hyperemia of the skin, angioedema.

Laboratory indicators: eosinophilia.

Other: very rarely - general weakness.

Overdose:

Symptoms: lowering blood pressure, accompanied by headache, tachycardia, dizziness and general weakness.

Treatment: symptomatic.

Interaction:

Strengthens coronarodilating and some antihypertensive drugs agents, cardiac glycosides.

In view of the possible development of moderate tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-blockers, hypotensive drugs and peripheral vasodilators.

You can combine with antianginal drugs, anticoagulants, antiaggregants, antiarrhythmic drugs, diuretics, bronchodilators.

Special instructions:

Meldonium is not a first-line drug in acute coronary syndrome and its use is not an urgent need.

Care should be taken when treating patients with chronic liver and kidney diseases, especially with prolonged use of the drug.

Effect on the ability to drive transp. cf. and fur:

There is no evidence of adverse effects of the drug on the rate of psychomotor reactions.

Form release / dosage:

Solution for injection 100 mg / ml.

Packaging:

5 ml into neutral glass ampoules.

For 10 ampoules with instruction for use and a knife for opening ampoules or a scarifier ampullum is placed in a box of cardboard.

5 or 10 ampoules are placed in a contiguous cell pack of a polyvinyl chloride film or a polyethylene terephthalate and aluminum foil tape, or polyethylene coated paper, or without a foil, or without paper.

For 1 or 2 contour squares with instructions for use and a vial ampoule or scarifier ampullum placed in a pack of cardboard.

When you pack the ampoules with a break ring or break point, the ampoule knife or ampoule scapegrator is not inserted.

Storage conditions:

In the dark place at a temperature of 15 to 25 ° C.

Keep out of the reach of children.

Shelf life:2 years. Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-002836

Date of registration:23.01.2015 / 08.10.2015

Expiration Date:23.01.2020

The owner of the registration certificate:NOVOSIBHIMFARM, OJSC NOVOSIBHIMFARM, OJSC Russia

Manufacturer: & nbsp

NOVOSIBHIMFARM, OJSC Russia

Information update date: & nbsp14.08.2017

Illustrated instructions

Instructions

Angiocarcinoma (Angiocardil)